2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17568
    Nonivamide 2444-46-4 98.74%
    Nonivamide is a agonist, which exhibits 4d-EC50 value of 5.1 mg/L in static toxicity tests.
    Nonivamide
  • HY-19518
    Latanoprostene bunod 860005-21-6 99.85%
    Latanoprostene bunod (LBN), a nitric oxide (NO)-donating prostaglandin F2a analog, is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (OHT) .
    Latanoprostene bunod
  • HY-B0423
    Neostigmine Bromide 114-80-7 99.91%
    Neostigmine (Eustigmin) Bromide is an orally active and reversible cholinesterase inhibitor that acts on myasthenia gravis to prolong and intensify the muscarinic and nicotinic effects of acetylcholine. Neostigmine Bromide can be used in anesthesia to reverse the neuromuscular blockade produced by competitive neuromuscular blockers.
    Neostigmine Bromide
  • HY-B0552
    Dibucaine 85-79-0 99.81%
    Dibucaine (Cinchocaine) is a sodium channel inhibitor. Dibucaine is a potent SChE inhibitor.
    Dibucaine
  • HY-B0569
    Hexamethonium Bromide 55-97-0 ≥98.0%
    Hexamethonium Bromide is a non-selective ganglionic nicotinic-receptor antagonist (nAChR) antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity. Hexamethonium Bromide attenuates sympathetic activity and blood pressure in spontaneously hypertensive animal models.
    Hexamethonium Bromide
  • HY-B1124
    Fipexide 34161-24-5
    Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection.
    Fipexide
  • HY-D0965
    Procion Blue HB 12236-82-7
    Procion Blue HB (Reactive Blue 2) is a purinergic antagonist.
    Procion Blue HB
  • HY-N0132
    Synephrine 94-07-5 ≥98.0%
    Synephrine (Oxedrine), an alkaloid, is an α-adrenergic and β-adrenergic agonist derived from the Citrus aurantium. Synephrine is a sympathomimetic compound and can be used for weight loss.
    Synephrine
  • HY-N0467
    Rebaudioside C 63550-99-2 99.90%
    Rebaudioside C (Dulcoside B) is an orally effective natural sweetener that cannot pass the blood-brain barrier and selectively binds to human sweet taste receptors (TAS1R2/TAS1R3). The sweetness of Rebaudioside C is about 20-30 times that of sucrose, and its sweetness activity depends on the C-16/C-17 double bond structure and specific aglycones. The glycoside structure in the Rebaudioside C molecule can bind to the sweet taste receptor, activate the taste signal transduction pathway, and produce sweetness perception.
    Rebaudioside C
  • HY-N2125
    Parishin C 174972-80-6 99.81%
    Parishin C, a parishin derivative isolated from Gastrodia elata, may have antioxidant property.
    Parishin C
  • HY-N7036
    Rhamnetin 90-19-7 99.18%
    Rhamnetin is a quercetin derivative found in Coriandrum sativum, inhibits secretory phospholipase A2 and histone deacetylase 2 (HDAC2). Rhamnetin exhibits antitumor, antioxidant and anti-inflammatory activity.
    Rhamnetin
  • HY-103228
    GYKI 53655 hydrochloride 143692-48-2 98.37%
    GYKI 53655 (LY300168) hydrochloride is an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonist.
    GYKI 53655 hydrochloride
  • HY-103516
    CGP55845 hydrochloride 149184-22-5 ≥99.0%
    CGP55845 hydrochloride is a potent and selective GABAB receptor antagonist with an IC50 of 6 nM. CGP55845 hydrochloride can be used for neurological research.
    CGP55845 hydrochloride
  • HY-103638
    3-Methoxytyramine hydrochloride 1477-68-5 ≥98.0%
    3-Methoxytyramine hydrochloride is an inactive metabolite of dopamine which can activate trace amine associated receptor 1 (TAAR1).
    3-Methoxytyramine hydrochloride
  • HY-105066
    Davunetide 211439-12-2 99.64%
    Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity.
    Davunetide
  • HY-108648
    2-MeS-ADP trisodium 475193-31-8 ≥99.0%
    2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
    2-MeS-ADP trisodium
  • HY-112266
    MARK-IN-4 1990492-86-8 99.63%
    MARK-IN-4 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of 1 nM. Inhibition of microtubule affinity regulating kinase (MARK) represents a potentially attractive means of arresting neurofibrillary tangle pathology in Alzheimer's disease.
    MARK-IN-4
  • HY-122026
    PF-04802367 1962178-27-3 98.43%
    PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively.
    PF-04802367
  • HY-124751
    YTX-465 2225824-53-1 99.06%
    YTX-465 is a stearoyl-CoA desaturase (Ole1/SCD) inhibitor. YTX-465 inhibits Ole1 and SCD1 with IC50s of 0.039 μM and 30.4 μM, respectively. YTX-465 can be used in the research of Parkinson’s disease and other synucleinopathies.
    YTX-465
  • HY-12798C
    AR-13503 2309668-15-1 98.21%
    AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research.
    AR-13503
Cat. No. Product Name / Synonyms Application Reactivity